Chester County News and Community Website
Galera Therapeutics, Inc. (Nasdaq: GRTX), headquartered in Malvern, PA, is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
MALVERN, PA — Galera Therapeutics, Inc. (OTC: GRTX) announced it has entered into an asset purchase agreement with Toronto-based Biossil Inc. for the sale of its dismutase mimetics portfolio, including …
Galera Therapeutics Sells Dismutase Mimetics Portfolio to Biossil in $108.5 Million Deal Read More MALVERN, PA — Galera Therapeutics, Inc. (OTC: GRTX) has announced its acquisition of Nova Pharmaceuticals, Inc., a biotechnology company focused on treating resistant forms of breast cancer, including metaplastic and …
Galera Therapeutics Acquires Nova Pharmaceuticals to Advance Breast Cancer Treatment Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) revealed this week that its Board of Directors has approved a Plan of Liquidation and Dissolution, contingent on stockholder approval. A special …
Galera Therapeutics Announces Plan of Liquidation and Dissolution Amid Financial Updates Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company, has released its financial outcomes for the first quarter ending March 31, 2024, and concurrently provided insights into …
Galera Therapeutics Explores Strategic Options Amid Financial Results Announcement Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) today unveiled a strategic move to safeguard its stockholders by adopting a limited duration stockholder rights agreement, commonly referred to as a …
Galera Therapeutics Implements Stockholder Rights Plan to Shield Investor Interests Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a key player in the pharmaceutical industry, recently unveiled its financial results for the fourth quarter and full year of 2023, which …
Galera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory Challenges Read More